by John Weeks, Publisher Editor of The Integrator Blog News & Reports NCCAM funded study on EDTA chelation therapy shows compelling value for people with diabetes The November 26, 2013 e news from the NIH NCCAM led with a title and link that
The November 26, 2013 e-news from the NIH NCCAM led with a title and link that will have the mainstream cardiology and endocrinology communities diving deep for hoped for methodological bungling. Entitled New TACT Analysis Shows EDT-Chelation Therapy Has Beneficial Outcomes for People with Diabetes. The brief by NCCAM director Josie Briggs, MD closed the first paragraph with: “EDTA-based chelation treatments produced a marked reduction in cardiovascular events and [reduction in] death in participants with diabetes.” Then, interestingly: “Furthermore, the results suggest that treatments had no benefit in those who did not have diabetes.” This is the second significant publication that has shown value from EDTA chelation therapy. The first, published in the Journal of the American Medical Association, found a slight, positive statistical significance relative to cardiac events in people with previous myocardial infarction. Briggs shared that, for the diabetes drill-down, the positive “effects are large” and “strongly” warrant future study. She adds that “these findings are a reminder that we need to keep an open mind in research, as scientific investigation is rich with examples of unexpected outcomes.”
Comment: The NCCAM significant investment in the EDTA-chelation trial has been viewed by NCCAM’s antagonists as one of the most insane of the agency’s boon-doggles. This study, more than the first, gives an attaboy to the agency for examining outcomes such as US Senator Harkin urged in the agency’s mandate: real world look at perhaps the most significant therapy, from an economic perspective, used by what were once called “alternative medical doctors.”
Clinic led by Dan Labriola, ND receives $560,000 Takeda grant to test naturopathic protocol for limiting adverse effects of firm’s Velcade drug
In an unusual and perhaps historic move, Millennium: The Takeda Oncology Company has granted Seattle Northwest Natural Clinic $560,000 for a two-year trial that will “focus on mitigating a potential side effect of Velcade, an FDA approved, targeted chemotherapy approved for the treatment of multiple myeloma and other cancers” according to an article in the Ballard News-Tribune. The clinic was founded by Dan Labriola, ND. The study will focus on a side effect, peripheral neuropathy, which manifests as numbness in the extremities. The writer continues: “Northwest Natural Clinic’s method, which has extensive anecdotal effectiveness, uses a combination of natural amino acid and a special form of Vitamin B to limit the neuropathy.”
Comment: Labriola has been a long-time leader in integrative oncology. His national visibility dates back to a study he had published in Oncology in 1999 that explored possible interactions between antioxidants and chemotherapy. His clinic has had a long affiliation with Swedish Hospital for which he is listed under physicians and providers. This appears to be a good sort of outcomes-type, researching the way we practice, real-world study that NIH NCCAM would be funding in spades were it to take seriously the rfal-world charge mentioned above and in Section C of its mandate.